Johnson & Johnson Advances Seltorexant and Electrophysiology Tech

Johnson & Johnson (NYSE: JNJ) has reported progress in its R&D pipeline, including clinical development of seltorexant for major depressive disorder.

The company is advancing novel antidepressant therapies alongside broader pharmaceutical initiatives, and also signed a multi-year agreement to expand access to advanced cardiac electrophysiology technologies in ambulatory surgery centers.

This focus on next-generation therapies and medical technologies highlights fresh momentum across both its pharmaceutical and MedTech operations.

Johnson & Johnson is one of the largest global healthcare companies, with a US$630.9b market cap and operations across pharmaceuticals and medical devices.